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Leishmaniasis is an infectious disease transmitted by the sand fly. It is caused by over 20 different species of
Leishmania and has affected over 14 million people worldwide. One of the main forms of control of leishmaniasis is
chemotherapy, but this is limited by the high cost and/or toxicity of available drugs. We previously found three
novel compounds with an iridoid tetracyclic skeleton to have activity against trypanosome parasites. In this study,
we determined the activity of the three anti-trypanosome compounds against Leishmania using field strain, 010,
and the lab strain Leishmania hertigi. The minimum inhibitory concentration (MIC) of the compounds against 010
was determined by microscopy while the IC50 of compounds against L. hertigi was determined by fluorescence-
activated cell sorting with Guava viacount analysis. We found two of the three compounds, molucidin and ML-F52,
to have anti-Leishmania activity against both strains. The fluor-microscope observation with DAPI stain revealed that
both Molucidin and ML-F52 induced abnormal parasites with two sets of nucleus and kinetoplast in a cell,
suggesting that compounds might inhibit cytokinesis in Leishmania parasites. Molucidin and ML-F52 might be
good lead compounds for the development of new anti-Leishmania chemotherapy.
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Leishmania is a protozoan parasite causing leishmania-
sis. Parasites are transmitted by the sand fly, and an esti-
mated 350 million people are at risk of infection in over
88 countries worldwide [1]. There are three forms of
leishmaniasis: cutaneous, muco-cutaneous, and visceral
leishmaniasis. The most common is cutaneous leishman-
iasis, caused by over 20 different Leishmania spp. and
characterized by ulcers or nodules on the skin. Muco-
cutaneous leishmaniasis, which is caused by parasites of* Correspondence: mikkvip@tmd.ac.jp
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liensis, Leishmania (V.) panamensis, and Leishmania
(V.) guyanensis, and also Leishmania amazonensis, is
characterized by a progressive destruction of the mucosa
by ulcers that spread from the mouth and nose to the
pharynx and larynx. The third form, visceral leishmania-
sis which is caused by Leishmania donovani and Leish-
mania infantum, is a systemic infection characterized by
prolonged fever, anemia, weight loss, hepatosplenome-
galy, and, in severe cases, death [2–6]. In Ghana, one of
the three ecological zones, arid Northern savanna, epide-
miologically lies within the leishmaniasis belt in Africa.
There have however been no reports of leishmaniasis in
this region of the country. Most reported cases of leish-
maniasis in Ghana have come from the Ho district of
the Volta Region which is the moist semi-deciduousle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Anti-Leishmania activity of three anti-trypanosome
compounds
Molucidin (μM) ML-2-3 (μM) ML-F52 (μM)
IC50 after 48 h (L. hertigi) 4.24 >50 3.38
MIC after 96 h (010) 4.17 >50 2.60
IC50 of amphotericin B (positive control) was 0.1 μg/ml
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(which may include muco-cutaneous, because of prob-
lems with diagnosis) is the only kind of leishmaniasis re-
ported in this region. The species of Leishmania
recorded in Ghana as the causative agent of cutaneous
leishmaniasis is Leishmania major [8]. More recently, a
new member of the Leishmania enriettii complex has
been detected and isolated in Ghana [9].
The main form of control of leishmaniasis is chemo-
therapy. The use of the current anti-Leishmania drugs
are however limited by high toxicity [10]. The treatment
of leishmaniasis involves the use of specific anti-Leish-
mania drugs and the aggressive management of any bac-
teria or parasitic co-infection, hypovolemia (decreased
blood volume), and malnutrition [10]. Pentavalent anti-
monials, the first line treatment for leishmaniasis, have
an efficacy dependent on the species of Leishmania, the
geographical location as well as the clinical presentation
of the disease [11]. The antimonials have also been re-
ported to have high toxicity that results in frequent and
life-threatening side effects [12]. The second line of
treatment, pentamidine and amphotericin B, is limited
by high toxicity and/or emergence of resistance [13].
Like the antimonials, the second line of treatment
requires parenteral administration. Last but not least,
Miltefosine, the only oral treatment for leishmaniasis, is
teratogenic and is therefore not suitable for women of
childbearing age [14].
Although the promastigote stage of the Leishmania
parasite is mainly found in the sand fly vector, their ease
of handling has made them a very useful tool in the de-
termination of the anti-Leishmania activity of com-
pounds and extracts. Also, promastigotes have been
reported to be a good option for the screening of com-
pounds whose anti-Leishmania activity is not dependent
of cell-mediated parasiticidal mechanisms [15]. This is
because their activities against the promastigote stage
would be representative of their activities against the
intracellular amastigotes [15].
In recent times, there have been several reports on the
use of medicinal plants for the treatment of various ail-
ments. Medicinal plants like Zanthoxyum zanthoxyloides
and Annona senegalensis have been reported to have
some anti-Leishmania activity [16, 17]. In our previous
study, we isolated three novel tetracyclic iridoid com-
pounds from Morinda lucida benth, Molucidin, ML-2-3,
and ML-F52 and found them to have anti-trypanosome
activity [18]. Leishmania species belongs to the same
kinetoplastid protozoan group with Trypanosoma and
shares very similar life cycle and organelles such as fla-
gellum and kinetoplast. In this study, we have tested
those novel compounds against Leishmania spp. and
found that two of these three compounds, Molucidin
and ML-F52, had activities against Leishmania species,suggesting Molucidin and ML-F52 to be promising lead
compounds for the treatment of leishmaniasis.
Materials and methods
Leishmania parasites
The field strain of L. enriettii (010) promastigotes, which
had been isolated in Ghana, and the lab strain, Leish-
mania hertigi promastigotes, were used in this study be-
cause of their availability. Parasites were cultured
in vitro according to conditions established previously
[19]. Log phase of parasites (1 × 106 parasites/ml) was
diluted to a parasitemia of 3 × 105 parasites/ml with
M199 medium and used for the drug assay. Estimation
of parasitemia was done with the Neubauer’s counting
chamber.
In vitro viacount assay for L. hertigi and the Ghanaian
field strain (010)
Leishmania promastigote forms of L. hertigi parasites
were seeded and incubated in the presence or absence of
(50–0.78 μM) compounds (dissolved in DMSO) for
48 h, after which the Guava reagent for viacount (Milli-
pore) was added to the culture in the ratio of 1:1 and
incubated for 30 min. Analysis was performed using the
Millipore guava easyCyte 5HT (USA) according to the
manufacture’s instruction.
Promastigotes of Leishmania 010 were seeded and
incubated in the presence or absence of (50–0.78 μM)
compounds for 96 h and the minimum inhibitory con-
centration (MIC) of the compounds determined by
microscopy.
Fluor-microscopy analysis using DAPI
Parasites were incubated for 24 h under appropriate con-
ditions (25 °C) with appropriate concentrations of active
compounds, Molucidin and ML-F52. Parasites were then
harvested and fixed with 4 % paraformaldehyde at room
temperature for 5 min. Washing steps were carried out
with PBS and PBST (0.1 % Triton X 100 in PBS) at room
temperature for 5 min and 15 min, respectively. The para-
sites were stained with 4’,6-diamidino-2’-phenylindole
dihydrochloride (DAPI) (5 μg/ml DAPI in PBS) for
10 min. After washing steps as above, the slides were
mounted using parmafluor mounting reagent and covered
with cover slips. The slides were observed under the
Olympus fluorescent microscope (Olympus BX53) to de-
tect any phenotypic changes in L. hertigi parasites.
Table 2 Selective index of compounds tested for anti-Leishmania activity
IC50 (μM), 48 h SI
ML-2-2 ML-2-3 ML-F52 ML-2-2 ML-2-3 ML-F52
IC50 of anti-leishmanial activity 4.24 >50 3.38
Normal skin fibroblasts NBIRGB 7.11 >50 4.74 1.67 >0.14 1.4
Normal lung fibroblasts HF-19 14.24 >50 10.94 3.36 >0.28 3.23
Normal lung Hs-888Lu 9.29 >50 8.89 2.19 >0.19 2.63
Normal liver Chang Liver 9.34 >50 18.13 2.20 >0.19 5.36
Fig. 1 Effect of Molucidin and ML-F52 on the nucleus, kinetoplast,
and morphology of the parasite. a DAPI staining and fluor-microscope
observation of parasites challenged with Molucidin and ML-F52. Both
compounds induced short stumpy like parasite without long flagellum
in which the cells having two sets of nucleus and kinetoplast in a cell
were observed (indicated by red arrowhead). b Graph showed the ratio
of normal cells which has one set of nucleus and kinetoplast (1N/1K)
and abnormal cells induced by compounds which has two sets
of nucleus and kinetoplast in a cell (2N/2K). 2N/2K cells were
significantly induced by both Molucidin and ML-F52
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Activity of compounds against Leishmania parasites
The aim of the study was to investigate the anti-Leish-
mania properties of the three novel tetracyclic iridoid
compounds previously found to have anti-trypanosome
activity. In the determination of the effect of Molucidin,
ML-2-3, and ML-F52 on L. hertigi and 010, parasites
were challenged with 0–50 μM of each compound for
48 and 96 h to determine MIC and the concentration of
compounds that inhibited parasite growth by 50 %
(IC50) by microscopy and fluorescence-activated cell
sorting (FACS) analysis, respectively. Molucidin and
ML-F52 had anti-Leishmania activity against both
strains while ML-2-3 had no activity. Molucidin showed
anti-L. hertigi activity with IC50 of 4.24 μM and anti-010
activity with MIC of 4.167 μM (Table 1). Compound
ML-F52 showed anti-L. hertigi activity with IC50 of
3.38 μM and anti-010 activity with MIC of 2.60 μM
(Table 1). All three compounds share same side chains,
iridoid tetracyclic skeleton, but differ in their functional
group region. Molucidin and ML-F52 are esters while
ML-2-3 is carboxylic acid. The functional groups may
play a key role in the activity of the compounds against
Leishmania. With respect to toxicity, ML-F52 had a
selective index (SI values) in the range of 1.4–5.36 while
Molucidin had SI values in the range of 1.67–2.20,
respectively (Table 2).
Effect of compounds on parasite morphology and flagella
function
To investigate the effect of Molucidin and ML-F52 on
the morphology and cell division of L. hertigi, we per-
formed fluor-microscope observation with DAPI staining
after incubation of parasite with 4 μM of Molucidin and
ML-F52 for 48 h. Both Molucidin and ML-F52 induced
short stumpy form parasite cells (Fig. 1a), in which two
sets of nucleus and kinetoplast were observed (2N/2K),
while normal cells had a set of nucleus and kinetoplast
in each cell (1N/1K). Microscopic counting resulted in
different ratios of both populations in Molucidin- and
ML-F52-treated Leishmania as follows: normal cells
(data not shown) and DMSO-treated cells showed 90 %
of 1N/1K and 10 % of 2N/2K, while both Molucidin and
ML-F52 caused significant increase with 30–40 % of 2N/2K and decrease of 1N/1K cells (Fig. 1b). These results
indicated that Molucidin and ML-F52 might inhibit
cytokinesis after division of both nuclei and kinetoplast
in Leishmania parasites since there was also no observ-
able inhibition of nuclear or kinetoplast division nor
signs of nuclear and/or kinetoplast disintegration or
fragmentation. This result indicated that Leishmania
parasites challenged with both Molucidin and ML-F52
were able to undergo both nuclei and kinetoplast div-
ision but are unable to progress through mitosis to form
two distinct daughter cells. The inability of cells to
undergo cytokinesis has been shown to cause cell cycle
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inhibition of cytokinesis might imply the inability of cells
to replicate in the mammalian host and increase the
parasite burden. This may prevent the parasites from
over running the host-immune and may give the host
the edge to clear the infection [22]. On the other hand,
this cell cycle inhibition may lead to the induction of
apoptosis-like death in the Leishmania cells and may be
the mechanism by which both compounds induce death
[23, 24]. In fact, we previously found cell cycle alteration
and apoptosis induction in Trypanosoma parasite chal-
lenged with ML-2-3 and ML-F52. Although there should
be further analysis done to elucidate the mechanism of
action for these compounds, they might be promising
lead compounds for the development of an alternate
anti-Leishmania drug.
Conclusion
Molucidin and ML-F52 are promising compounds for
the development of novel anti-Leishmania drugs. The
development of one or both compounds may lead to the
development of a safer, cheaper, and relatively more
available drug(s) for the treatment of leishmaniasis.
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